Deranged cellular metabolism is a hallmark of cancer. Although we are learning much about the role of altered metabolism in acute myeloid leukemia, the role of metabolism in treatment resistance in ALL is poorly understood. Our previous work identified cells with active mTOR signaling (Good et al. Nature Medicine 2018) to be predictive of future relapse when found at diagnosis. Further analysis of this signaling signature has identified a unique metabolic state and new potential therapeutic vulnerabilities.